One phase II study did not find any substantial benefit of CoQ10 supplementation in patients with ALS (Kauffman 2009)
After weighting, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with DPP-4 inhibitors (weighted incidence rate 3.9 (95% CI 3.5 to 4.4) v 3.7 (3.6 to 3.9) per 1000 person years, respectively
If you've been stacking products without clear progress, this might be the explanation you've been looking for
Global cancer control: responding to the growing burden, rising costs and inequalities in access
If you start a GLP-1, your care team will check in after a few weeks, and you can message your clinician anytime through the Nice app with questions or updates
The KFF brief points out that if all states covered obesity drugs, about 40% of Medicaid adults and 26% of Medicaid children with obesity could gain access to these medications ( [38] )